Skip to main content
SpringerLink
Log in

Prophylactic Treatment of the Pelvic Lymphatics: Contra

  • Chapter
  • First Online:
Book cover Radiotherapy in Prostate Cancer

Part of the book series: Medical Radiology ((Med Radiol Radiat Oncol))

  • 1888 Accesses

Abstract

According to the opinion of the author, to date—applying evidence-based medicine—physicians should not perform prophylactic pelvic lymph node irradiation in routine practice for locally advanced prostate cancer because of the lack of any demonstrated benefit. In addition, this treatment has a higher risk of acute and late toxicities. Standard prognostic factors and nomograms, failed to identify a subgroup of patients who may benefit from pelvic lymph nodes irradiation. Several biases including technical radiotherapy features (target volume, dose) are discussed. Radiation oncologists should be encouraged to participate in the ongoing RTOG 094 international randomized study.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Asbell SO, Krall JM, Pilepich MV et al (1988) Elective pelvic irradiation in stage A2, B carcinoma of the prostate: analysis of RTOG 77-06. Int J Radiat Oncol Biol Phys 15(6):1307–1316

    Article  CAS  PubMed  Google Scholar 

  • Asbell SO, Martz KL, Shin KH et al (1998) Impact of surgical staging in evaluating the radiotherapeutic outcome in RTOG #77-06, a phase III study for T1BN0M0 (A2) and T2N0M0 (B) prostate carcinoma. Int J Radiat Oncol Biol Phys 40(4):769–782

    Article  CAS  PubMed  Google Scholar 

  • Briganti A, Chun FK, Karakiewicz P et al (2008) Is node-positive prostate cancer always a systemic disease? Eur Urol 54(2):243–246

    Google Scholar 

  • Briganti A, Karnes J, Da Pozzo L et al (2008b) Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 784 consecutive N+ patients. Eur Urol 7:303

    Article  Google Scholar 

  • Briganti A, Karnes JR, Da Pozzo LF et al (2009) Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. a new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy. Eur Urol 55(2):261–270

    Article  PubMed  Google Scholar 

  • Briganti A, Larcher A, Abdollah F et al (2012) Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores. Eur Urol 61(3):480–487

    Article  PubMed  Google Scholar 

  • D’Amico AV, Whittington R, Malkowicz SB et al (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280:969–974

    Article  PubMed  Google Scholar 

  • Ganswindt U, Paulsen F, Corvin S et al (2007) Optimized coverage of high-risk adjuvant lymph node areas in prostate cancer using a sentinel node-based, intensity-modulated radiation therapy technique. Int J Radiat Oncol Biol Phys 67(2):347–355

    Article  PubMed  Google Scholar 

  • Guerrero Urbano T, Khoo V, Staffurth J et al (2010) Intensity-modulated radiotherapy allows escalation of the radiation dose to the pelvic lymph nodes in patients with locally advanced prostate cancer: preliminary results of a phase I dose escalation study. Clin Oncol (R Coll Radiol) 22(3):236–244

    Article  CAS  Google Scholar 

  • Heidenreich A, Ohlmann CH, Polyakov S (2007) Anatomical extent of pelvic lymphadenectomy in patients undergoing radical prostatectomy. Eur Urol 52:29–37

    Article  PubMed  Google Scholar 

  • Hwang AB, Chen J, Nguyen TB et al (2012) Irradiation of the prostate and pelvic lymph nodes with an adaptive algorithm. Med Phys 39(2):1119–1124

    Article  CAS  PubMed  Google Scholar 

  • Jacob R, Hanlon AL, Horwitz EM et al (2005) Role of prostate dose escalation in patients with greater than 15 % risk of pelvic lymph node involvement. Int J Radiat Oncol Biol Phys 61:695–701

    Article  PubMed  Google Scholar 

  • Jereczek-Fossa BA, Beltramo G, Fariselli L et al (2012) Robotic image-guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastatic prostate cancer. Int J Radiat Oncol Biol Phys 82(2):889–897

    Article  PubMed  Google Scholar 

  • Jilg CA, Rischke HC, Reske SN et al (2012) Salvage lymph node dissection with adjuvant radiotherapy for nodal recurrence of prostate cancer. J Urol 188(6):2190–2197

    Article  CAS  PubMed  Google Scholar 

  • Lawton CA, DeSilvio M, Roach M et al (2007) An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys 69:646–655

    Article  PubMed Central  PubMed  Google Scholar 

  • Lawton CA, Michalski J, El-Naqa I et al (2009) RTOG GU Radiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 74(2):383–387

    Article  PubMed Central  PubMed  Google Scholar 

  • Muren LP, Wasbø E, Helle SI et al (2008) Intensity-modulated radiotherapy of pelvic lymph nodes in locally advanced prostate cancer: planning procedures and early experiences. Int J Radiat Oncol Biol Phys 71(4):1034–1041

    Article  PubMed  Google Scholar 

  • Pan CC, Kim KY, Taylor JM (2002) Influence of 3D-CRT pelvic irradiation on outcome in prostate cancer treated with external beam radiotherapy. Int J Radiat Oncol Biol Phys 53:1139–1145

    Article  CAS  PubMed  Google Scholar 

  • Pilepich MV, Krall JM, Johnson RJ et al (1986) Extended field (periaortic) irradiation in carcinoma of the prostate–analysis of RTOG 75-06. Int J Radiat Oncol Biol Phys 12(3):345–351

    Article  CAS  PubMed  Google Scholar 

  • Pollack A, Zagars GK, Starkschall G et al (2002) Prostate cancer radiation dose response: results of the MD Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53:1097–1105

    Article  PubMed  Google Scholar 

  • Pommier P, Chabaud S, Lagrange JL et al (2007) Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01. J Clin Oncol 25:5366–5373

    Article  PubMed  Google Scholar 

  • Roach M, Marquez C, Yuo HS et al (1994) Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 28:33–37

    Article  PubMed  Google Scholar 

  • Roach M III, DeSilvio M, Lawton C et al (2003) Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: radiation Therapy Oncology Group 9413. J Clin Oncol 21:1904–1911

    Article  PubMed  Google Scholar 

  • Roach M 3rd, DeSilvio M, Valicenti R et al (2006) Whole-pelvis, “mini-pelvis,” or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the radiation therapy oncology group 9413 trial. Int J Radiat Oncol Biol Phys 66(3):647–653

    Article  PubMed  Google Scholar 

  • Shih H, Harisinghani M, Zietman A et al (2005) Mapping of nodal disease in locally advanced prostate cancer: rethinking the clinical target volume for pelvic nodal irradiation based on vascular rather than bony anatomy. Int J Radiat Oncol Biol Phys 63:1262–1269

    Article  PubMed  Google Scholar 

  • Swanson GP, Thompson IM, Basler J (2006) Treatment options in lymph node-positive prostate cancer. Cancer 106(12):2531–2539

    Article  PubMed  Google Scholar 

  • Taylor A, Rockall A, Reznek R et al (2005) Mapping pelvic lymph nodes: guidelines for delineation in intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 63:1604–1612

    Article  PubMed  Google Scholar 

  • Vargas CE, Galalae R, Demanes J et al (2005) Lack of benefit of pelvic radiation in prostate cancer patients with a high risk of positive pelvic lymph nodes treated with high-dose radiation. Int J Radiat Oncol Biol Phys 63:1474–1482

    Article  PubMed  Google Scholar 

  • Vargas C, Martínez A, Galalae R et al (2006) High-dose radiation employing external beam radiotherapy and high-dose rate brachytherapy with and without neoadjuvant androgen deprivation for prostate cancer patients with intermediate- and high-risk features. Prostate Cancer Prostatic Dis 9(3):245–253

    Article  CAS  PubMed  Google Scholar 

  • Walz J, Bladou F, Rousseau B et al (2012) Head to head comparison of nomograms predicting probability of lymph node invasion of prostate cancer in patients undergoing extended pelvic lymph node dissection. Urology 79(3):546–551

    Article  PubMed  Google Scholar 

  • Wang-Chesebro A, Xia P, Coleman J, Akazawa C, Roach M 3rd (2006) Intensity-modulated radiotherapy improves lymph node coverage and dose to critical structures compared with three-dimensional conformal radiation therapy in clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 66(3):654–662

    Article  PubMed  Google Scholar 

  • Weckermann D, Goppelt M, Dorn R et al (2006) Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate-specific antigen (PSA) level of < or = 10 ng/mL and biopsy Gleason score of < or = 6, and their influence on PSA progression-free survival after radical prostatectomy. BJU Int 97(6):1173–1178

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Radiotherapy Department, Centre Léon Bérard, 28 Rue Laënnec, 69373, Lyon CEDEX 08, France

    Pascal Pommier

Authors
  1. Pascal Pommier
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pascal Pommier .

Editor information

Editors and Affiliations

  1. Department of Radiation Oncology, Krankenhaus der Barmherzigen, Schwestern Linz, Johannes Kepler University, Linz, Austria

    Hans Geinitz

  2. University of California, San Francisco Department of Radiation Oncology, San Francisco, California, USA

    Mack Roach III

  3. The Institute of Cancer Research Sutton, Sutton Surrey, United Kingdom

    Nicholas van As

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Pommier, P. (2014). Prophylactic Treatment of the Pelvic Lymphatics: Contra. In: Geinitz, H., Roach III, M., van As, N. (eds) Radiotherapy in Prostate Cancer. Medical Radiology(). Springer, Berlin, Heidelberg. https://doi.org/10.1007/174_2013_949

Download citation

  • DOI: https://doi.org/10.1007/174_2013_949

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-37098-4

  • Online ISBN: 978-3-642-37099-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation